{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:19:15Z","timestamp":1757618355035,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The third known case in the country of Tyrosinemia type 1 is presented, a 10-month-old male infant who was referred to the emergency room due to hepatomegaly, compromised liver function, neurological deterioration, and abnormal urinary amino acids findings. Given the persistence of hepatic deterioration and focal hepatic lesions, a high clinical suspicion of Tyrosinemia type 1 was considered, and targeted treatment with Nitisinone and a restrictive diet was initiated, resulting in an appropriate clinical and tests response. However, there was an abrupt discontinuation of the medication without any medical indication, added to the fact that elevated succinylacetone levels were later reviewed, the main diagnosis was confirmed. The medication was continued, but the patient experienced adverse events related to it, requiring multiple dose adjustments provided by the medical team. Tyrosinemia type I is a rare disease and therefore difficult to diagnose, requiring extensive knowledge for timely and accurate treatment. Hence, the importance of acknowledging the management of these adverse events is crucial. The aim of this article is to present a rare clinical case and propose a desensitization protocol for Nitisinone for those cases that present adverse reactions to the medication.<\/jats:p>","DOI":"10.1186\/s13023-025-03666-8","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:27:10Z","timestamp":1751444830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nitisinone desensitization protocol, case report of hereditary Tyrosinemia type 1 with successful treatment and outcomes"],"prefix":"10.1186","volume":"20","author":[{"given":"Michael","family":"Vallejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4038-8123","authenticated-orcid":false,"given":"Valentina","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Alejandra","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bachiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malory","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyssethe Juliana","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"3666_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.101","author":"JM Chinsky","year":"2017","unstructured":"Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, Waisbren SE, Gucsavas-Calikoglu M, Wasserstein MP, Coakley K, Scott CR. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017. https:\/\/doi.org\/10.1038\/gim.2017.101.","journal-title":"Genet Med"},{"issue":"4","key":"3666_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6002\/ect.2013.0158","volume":"13","author":"A Bahador","year":"2015","unstructured":"Bahador A, Dehghani SM, Geramizadeh B, Nikeghbalian S, Bahador M, Malekhosseini SA, Kazemi K, Salahi H. Liver transplant for children with hepatocellular carcinoma and hereditary Tyrosinemia type 1. Exp Clin Transplant. 2015;13(4):329\u201332. https:\/\/doi.org\/10.6002\/ect.2013.0158.","journal-title":"Exp Clin Transplant"},{"key":"3666_CR3","unstructured":"Toapanta Ortiz A. Tirosinemia Tipo I. http:\/\/dspace.espoch.edu.ec\/bitstream\/123456789\/9050\/1\/94T00352.pdf, 2018 [accessed 15 April 2024]."},{"issue":"18","key":"3666_CR4","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1074\/jbc.RA117.000347","volume":"293","author":"Y Shao","year":"2019","unstructured":"Shao Y, Wang L, Guo N, Wang S, Yang L, Li Y, Wang M, Yin S, Han H, Zeng L, Zhang L, Hui L, Ding Q, Zhang J, Geng H, Liu M, Li D. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats. J Biol Chem. 2019;293(18):6883\u201392. https:\/\/doi.org\/10.1074\/jbc.RA117.000347.","journal-title":"J Biol Chem"},{"key":"3666_CR5","unstructured":"Fuentes-Cort\u00e9s I, Pacheco-Su\u00e1rez B, Char\u00f3n-Sav\u00f3n D. Implementaci\u00f3n de una metodolog\u00eda para la detecci\u00f3n de marcadores bioqu\u00edmicos en la tirosinemia tipo 1. Finlay. 2023; 13(4): 425\u201334. https:\/\/revfinlay.sld.cu\/index.php\/finlay\/article\/view\/1317"},{"issue":"3","key":"3666_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0120-4912(15)30136-1","volume":"47","author":"S Ardila","year":"2014","unstructured":"Ardila S, Echeverri OY, Guevara J, Espinosa E, Barrera LA. Tirosinemia de tipo I, aciertos y errores. Pediatr\u00eda. 2014;47(3):55\u20139.","journal-title":"Pediatr\u00eda"},{"key":"3666_CR7","doi-asserted-by":"publisher","unstructured":"Kaye CI; Committee on Genetics; Accurso F, La Franchi S, Lane PA, Hope N, Sonya P, Bradley S, Michele A LP. Newborn screening fact sheets. Pediatrics. 2006 Sep;118 (3):e934-63. https:\/\/doi.org\/10.1542\/peds.2006-1783","DOI":"10.1542\/peds.2006-1783"},{"key":"3666_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-319-55780-9_14","volume":"959","author":"I Ibarra-Gonz\u00e1lez","year":"2017","unstructured":"Ibarra-Gonz\u00e1lez I, Ridaura-Sanz C, Fern\u00e1ndez-Lainez C, Guill\u00e9n-L\u00f3pez S, Belmont-Mart\u00ednez L, Vela-Amieva M. Hepatorenal Tyrosinemia in Mexico: a call to action. Adv Exp Med Biol. 2017;959:147\u201356. https:\/\/doi.org\/10.1007\/978-3-319-55780-9_14.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"3666_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/TACG.S113310","volume":"24","author":"AM Das","year":"2017","unstructured":"Das AM. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1). Appl Clin Genet. 2017;24(10):43\u20138. https:\/\/doi.org\/10.2147\/TACG.S113310.","journal-title":"Appl Clin Genet"},{"issue":"3","key":"3666_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymgme.2014.07.021","volume":"113","author":"A Maiorana","year":"2014","unstructured":"Maiorana A, Malamisura M, Emma F, Boenzi S, Di Ciommo VM, Dionisi-Vici C. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1. Mol Genet Metab. 2014;113(3):188\u201393. https:\/\/doi.org\/10.1016\/j.ymgme.2014.07.021.","journal-title":"Mol Genet Metab"},{"key":"3666_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-319-55780-9_11","volume":"959","author":"AM Das","year":"2017","unstructured":"Das AM, Mayorandan S, Janzen N. Diagnosing hepatorenal tyrosinaemia in europe: newborn mass screening versus selective screening. Adv Exp Med Biol. 2017;959:125\u201332. https:\/\/doi.org\/10.1007\/978-3-319-55780-9_11.","journal-title":"Adv Exp Med Biol"},{"key":"3666_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-3-662-63123-2_17","volume-title":"Inborn Metabolic Diseases","author":"A Chakrapani","year":"2022","unstructured":"Chakrapani A, Gissen P, McKiernan P. Disorders of Tyrosine Metabolism. In: Inborn Metabolic Diseases. Berlin: Springer; 2022. p. 355\u201367."},{"key":"3666_CR13","unstructured":"Sniderman King L, Trahms C, Scott CR. Tyrosinemia Type I. In: Adam MP, Feldman J, Mirzaa GM, et al., eds. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; May 25, 2017. PMID: 20301688"},{"issue":"1","key":"3666_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13023-020-01547-w","volume":"15","author":"L \u00c4\u00e4rel\u00e4","year":"2020","unstructured":"\u00c4\u00e4rel\u00e4 L, Hiltunen P, Soini T, et al. Type 1 tyrosinemia in Finland: a nationwide study. Orphanet J Rare Dis. 2020;15(1):281.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3666_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1665-2681(19)30890-7","volume":"13","author":"C Fern\u00e1ndez-Lainez","year":"2014","unstructured":"Fern\u00e1ndez-Lainez C, Ibarra-Gonz\u00e1lez I, Belmont-Mart\u00ednez L, Monroy-Santoyo S, Guill\u00e9n-L\u00f3pez S, Vela-Amieva M. Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico. Ann Hepatol. 2014;13(2):265\u201372.","journal-title":"Ann Hepatol"},{"issue":"2","key":"3666_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ped.12503","volume":"57","author":"AC Zeybek","year":"2015","unstructured":"Zeybek AC, Kiykim E, Soyucen E, et al. Hereditary Tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int. 2015;57(2):281\u20139. https:\/\/doi.org\/10.1111\/ped.12503.","journal-title":"Pediatr Int"},{"issue":"8","key":"3666_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/archdischild-2014-306886","volume":"100","author":"PJ McKiernan","year":"2015","unstructured":"McKiernan PJ, Preece MA, Chakrapani A. Outcome of children with hereditary tyrosinemia following newborn screening. Arch Dis Child. 2015;100(8):738\u201341. https:\/\/doi.org\/10.1136\/archdischild-2014-306886.","journal-title":"Arch Dis Child"},{"key":"3666_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-55780-9_17","volume":"959","author":"F Alvarez","year":"2017","unstructured":"Alvarez F, Atkinson S, Bouchard M, Brunel-Guitton C, Buhas D, Bussieres JF, et al. The Quebec NTBC study. Adv Exp Med Biol. 2017;959:187\u201395. https:\/\/doi.org\/10.1007\/978-3-319-55780-9_17.","journal-title":"Adv Exp Med Biol"},{"key":"3666_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-3-319-55780-9_13","volume":"959","author":"Y Gigu\u00e8re","year":"2017","unstructured":"Gigu\u00e8re Y, Berthier MT. Newborn screening for hereditary Tyrosinemia Type I in Qu\u00e9bec: update. Adv Exp Med Biol. 2017;959:139\u201346. https:\/\/doi.org\/10.1007\/978-3-319-55780-9_13.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"3666_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40272-019-00364-4","volume":"21","author":"WG Van Ginkel","year":"2019","unstructured":"Van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-term outcomes and practical considerations in the pharmacological management of Tyrosinemia Type 1. Paediatr Drugs. 2019;21(6):413\u201326. https:\/\/doi.org\/10.1007\/s40272-019-00364-4.","journal-title":"Paediatr Drugs"},{"issue":"11","key":"3666_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/ped.13697","volume":"60","author":"K Kurihara","year":"2018","unstructured":"Kurihara K, Toyoda H, Amoano K, et al. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1. Pediatr Int. 2018;60(11):1039\u201341. https:\/\/doi.org\/10.1111\/ped.13697.","journal-title":"Pediatr Int"},{"key":"3666_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-319-55780-9_18","volume":"959","author":"FJ Van Spronsen","year":"2017","unstructured":"Van Spronsen FJ, van Rijn M, Meyer U, Das AM. Dietary considerations in Tyrosinemia Type I. Adv Exp Med Biol. 2017;959:197\u2013204. https:\/\/doi.org\/10.1007\/978-3-319-55780-9_18.","journal-title":"Adv Exp Med Biol"},{"key":"3666_CR23","doi-asserted-by":"publisher","unstructured":"Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline [published correction appears in Genet Med. 2014 Apr;16(4):356]. Genet Med. 2014;16(2):188\u2013200. https:\/\/doi.org\/10.1038\/gim.2013.157","DOI":"10.1038\/gim.2013.157"},{"key":"3666_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-55780-9_9","volume":"959","author":"WG Van Ginkel","year":"2017","unstructured":"Van Ginkel WG, Pennings JP, van Spronsen FJ. Liver cancer in Tyrosinemia Type 1. Adv Exp Med Biol. 2017;959:101\u20139. https:\/\/doi.org\/10.1007\/978-3-319-55780-9_9.","journal-title":"Adv Exp Med Biol"},{"key":"3666_CR25","unstructured":"Nitisinone, Drugbank online. https:\/\/go.drugbank.com\/drugs\/DB00348, 2023 (accessed 25 April 2024)."},{"key":"3666_CR26","unstructured":"Nitisinona, Asociaci\u00f3n espa\u00f1ola de pediatr\u00eda. https:\/\/www.aeped.es\/comite-medicamentos\/pediamecum\/nitisinona, 2020 (accessed 15 April 2024)."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03666-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:35:04Z","timestamp":1757205304000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03666-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03666-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Acknowledgments Section has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional Ethics Committee of Surgery Society of Hospital de San Jos\u00e9 de Bogot\u00e1 approved this study. All adults provided written informed consent and underage participants were asked to sign an informed assent form in addition to the consent form signed by the parents or guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Both the patient and his legal guardian provided informed consent for the data analysis and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}